To include your compound in the COVID-19 Resource Center, submit it here.

Therapeutics: Multiple kinase targets; an undisclosed target

Cancer

INDICATION: Cancer; breast cancer; lung cancer

Mouse studies suggest the mitochondrial inhibitor ME-344 and/or the multikinase inhibitor Vargatef nintedanib could help treat kinase inhibitor-resistant cancers. In a mouse model of Stivarga regorafenib-resistant metastatic breast

Read the full 332 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE